ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy, Tolerability, and Safety of DFN-15

ClinicalTrials.gov ID: NCT03009019

Public ClinicalTrials.gov record NCT03009019. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 1:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura

Study identification

NCT ID
NCT03009019
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
BioDelivery Sciences International
Industry
Enrollment
631 participants

Conditions and interventions

Interventions

  • DFN-15 Active Drug
  • DFN-15 Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2016
Primary completion
Oct 31, 2017
Completion
Apr 30, 2019
Last update posted
Jan 9, 2023

2016 – 2019

United States locations

U.S. sites
43
U.S. states
28
U.S. cities
42
Facility City State ZIP Site status
Site 609 Birmingham Alabama 35205
Site 640 Mobile Alabama 36608
Site 622 Tucson Arizona 85745
Site 616 Hot Springs Arkansas 71901
Site 637 Huntington Beach California 92647
Site 615 Oakland California 94607
Site 646 San Diego California 92108
Site 619 San Francisco California 94102
Site 624 San Marcos California 92078
Site 631 Littleton Colorado 80127
Site 603 Miami Florida 33176
Site 641 Orange City Florida 32763
Site 629 Orlando Florida 32801
Site 601 West Palm Beach Florida 33409
Site 625 Decatur Georgia 30034
Site 630 Sandy Springs Georgia 30328
Site 642 Meridian Idaho 83642
Site 604 Blue Island Illinois 60406
Site 602 Louisville Kentucky 40213
Site 644 New Orleans Louisiana 70115
Site 610 New Orleans Louisiana 70124
Site 634 Ann Arbor Michigan 48104
Site 623 Edina Minnesota 55435
Site 638 City of Saint Peters Missouri 63303
Site 606 Missoula Montana 59808
Site 613 Omaha Nebraska 68134
Site 647 Lebanon New Hampshire 03756
Site 618 Nashua New Hampshire 03060
Site 636 Albuquerque New Mexico 87102
Site 645 Brooklyn New York 11229
Site 608 Rochester New York 14609
Site 620 High Point North Carolina 27262
Site 643 Mooresville North Carolina 28117
Site 626 Fargo North Dakota 58103
Site 628 Cleveland Ohio 44122
Site 614 Warwick Rhode Island 02886
Site 639 Mt. Pleasant South Carolina 29464
Site 612 Dakota Dunes South Dakota 57049
Site 627 Austin Texas 78745
Site 611 Dallas Texas 75231
Site 632 San Antonio Texas 78240
Site 621 Taylorsville Utah 84123
Site 635 Richmond Virginia 23294

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03009019, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 9, 2023 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03009019 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →